Standout Papers

Immune Checkpoint Inhibitor Rechallenge After Immune-Related Adverse Events in Patients With Cancer 2020 2026 2022 2024364
  1. Immune Checkpoint Inhibitor Rechallenge After Immune-Related Adverse Events in Patients With Cancer (2020)
    Charles Dolladille, Stéphane Éderhy et al. JAMA Oncology

Immediate Impact

2 by Nobel laureates 56 standout
Sub-graph 1 of 23

Citing Papers

Adjuvant sintilimab in resected high-risk hepatocellular carcinoma: a randomized, controlled, phase 2 trial
2024 Standout
Paradigm Shift: A Comprehensive Review of Ovarian Cancer Management in an Era of Advancements
2024 Standout
2 intermediate papers

Works of Basile Chrétien being referenced

Myelodysplastic syndrome and acute myeloid leukaemia in patients treated with PARP inhibitors: a safety meta-analysis of randomised controlled trials and a retrospective study of the WHO pharmacovigilance database
2020
Immune Checkpoint Inhibitor Rechallenge After Immune-Related Adverse Events in Patients With Cancer
2020 Standout

Author Peers

Author Last Decade Papers Cites
Basile Chrétien 49 41 179 510 199 43 871
Jacob Colsky 2 8 74 448 174 40 892
Marion Sassier 48 52 97 644 247 38 958
Terenig Terjanian 2 17 154 476 175 30 905
Atif Hussein 2 12 163 308 217 55 794
Herbert Stöger 13 194 549 254 68 1.1k
Richard K. Desser 3 2 167 428 354 30 995
Lars Harbaum 14 177 310 365 48 886
Charalampos S. Floudas 7 23 163 657 194 59 1.0k
R B Jones 1 14 180 390 109 27 853
Hao Chen 1 15 209 527 146 28 867

All Works

Loading papers...

Rankless by CCL
2026